Clinical Trial Award
About this scheme
Applications must be:
- From a UK university, research institution, clinical centre or clinical trials unit (CTU)
- For investigator-led, interventional studies of cancer treatment
- Developed with the involvement of an experienced CTU
The types of studies that fit this scheme are typically:
- Phase 1a/2 dose finding trials testing safety, tolerability and preliminary efficacy (including novel combinations of therapies and radiotherapy, and novel indications)
- Phase 1b/2 or phase 2 trials testing the viability of larger trials, including the ability to recruit and/or to explore tolerability or efficacy of treatments
- Window of opportunity studies
- Phase 2/3 or phase 3 trials to investigate the efficacy, effectiveness and tolerability of interventions with the aim of improving survival.
Studies of cancer treatment approaches that aim to achieve equivalence of survival whilst reducing toxicity or optimising treatment delivery will be considered where the potential for a significant impact on patient outcomes can be demonstrated.
Funding for translational research that is directly linked to the clinical trial question can be requested in applications to this scheme. This can include, but is not limited to, stratification of patients or validation of biomarkers of response/resistance to the intervention being investigated in the trial.
If your proposal includes research that seeks to enable the early detection of cancer or pre-cancerous states, you may be eligible for our early detection funding opportunities.
If your study is an early phase trial requiring full management/support from our Centre for Drug Development you should consider the Drug Development Project scheme. If your project involves preclinical studies of new drug combinations you should consider the Preclinical Combination Grants scheme.
If your study is first in human/first in class but does not require management/support from our Centre for Drug Development, please contact us to discuss your study in more detail and for advice on the most appropriate scheme.
This scheme will not fund:
- Preclinical work
- Industry sponsored trials
- Sample collection in the absence of translational research that is directly linked to the clinical trial question and included in the application. If you wish to collect samples within a clinical trial and either it is not yet possible to generate specific research questions, or the specific questions have been generated but the funding to carry out the work has been or will be obtained elsewhere, you should consider the Prospective Sample Collection Award scheme.
- Discovery research with the aim of identifying or understanding the biological significance of potential biomarkers, understanding biological mechanisms of therapeutic interventions, or mechanisms of resistance to therapies. If you wish to carry out work of this nature, you may be eligible for our discovery research opportunities.
Funding can be used for:
- Salaries for researchers and technical staff
- Running expenses
Read our costs guidance for full details of the costs you can claim in your application.
*Typically up to 4 years for early phase or feasibility studies, and up to 10 years for late phase trials
**Typically up to £50,000 per year for early phase or feasibility studies, and up to £150,000 per year for late phase trials
Larger amounts may be considered with appropriate justification, particularly where substantial translational research is included.
How to apply to this scheme
Applications for this scheme are considered twice a year. Your application will follow either a 2- or 3-stage process:
- Proposal: submit a two-page proposal to the CRUK office. We will check that your proposal is within remit and confirm whether an outline is required.
- Outline applications: this stage can be ommitted for some applications (see below)
- Full applications:
- Submit your full application through our electronic Grants Management System
- Your application will be sent for peer review by international experts and by the relevant NCRI Clinical Studies Group, Advisory Groups and/or Strategic Groups
- You will be given the opportunity to respond to the peer review comments
- One of our Expert Review Panels (ERP) will consider your application, the reviews, and your response to the reviews, and you may be invited to present to the ERP before they make a recommendation to the Committee
- The Clinical Research Committee will make a final decision on funding
We will confirm whether an outline application is required after you submit your proposal form, but an outline application can typically be omitted where one of the following applies:
- You are applying for less than £500,000 of funding
- You are applying for endorsement only
- Your study follows seamlessly on from a feasibility study previously funded by CRUK
- You are requesting funding for the UK component of an internationally-led clinical trial
- You are applying for a costed amendment or extension to an existing study supported by CRUK
Outline application deadline
Full application deadline
Committee final decision
14 June 2018
20 September 2018
TBC - January 2019
TBC - March 2019
TBC - June 2019
Before you begin your application
- You must read the application guidelines (PDF) before starting your application, even if you have applied for funding with us before.
- You must read the costs guidance (PDF) to understand what we will and will not fund.
- We expect applications to have been discussed with the relevant NCRI Clinical Studies Group or Advisory Group.
- We expect patient and public involvement to be demonstrated in applications. Use our Patient and Public Involvement Toolkit for Researchers for advice on this.
- The NIHR CRN can provide support on a number of aspects of study development, set up and delivery through their Study Support Service. Applications must be costed in line with AcoRD guidance.
The Clinical Research Committee and its Expert Review Panels will judge your proposal based on the following criteria:
- Clinical and scientific importance of the research questions
- Alignment with our Research Strategy and Clinical Research Statement of Intent
- Expected impact on clinical practice
- Strength of study design, including statistical design and rationale
- Adequacy of background and supporting evidence
- Expected interest to patients and adequacy of the recruitment plan and supporting evidence
- Expertise of the study team
- Likelihood of successful study delivery
- Appropriate patient involvement
- Appropriate justification of costs
Does this scheme accept endorsements?
Yes. Academically-sponsored studies in receipt of educational grants and/or free drugs from the pharmaceutical industry can be submitted for CRUK endorsement.
Industry-sponsored trials cannot be reviewed under this scheme.
Does this scheme accept extension applications?
Under exceptional circumstances, applications for extensions to funding are accepted under this scheme. Please contact the Clinical Research Funding team to discuss the need for an extension and for access to an extension application form. You must read the extension application guidelines (PDF) before starting your application, even if you have applied for funding with us before.
Requests for no-cost extensions are also considered. Please contact the Clinical Research Funding team to discuss the need for an extension and for access to a no-cost extension form.
Does this scheme accept amendment applications?
Yes. Amendments must be reviewed by the Committee where there is a significant change to the study design, sample size or study drug. There are two routes for review of amendments:
- Review at a Committee meeting: this applies where additional funding is being requested. An amendment application must be submitted to the advertised deadline for that funding round and will be reviewed at a Committee meeting. Please contact the Clinical Research Funding team to discuss the need for an amendment and for access to an amendment application form. You must read the amendment application guidelines (PDF) before starting your application, even if you have applied for funding with us before.
- Out of Committee Review: this applies where no funding is being requested for the amendment. An amendment application must be submitted, which will be reviewed outside of the Committee meeting. A faster review is usually possible for this route. Please contact the Clinical Research Funding team to discuss the need for an amendment and for access to a no-cost amendment form.
Cancer Research UK contact details
Applications from Wales
Dr Caroline Dalton
Senior Research Funding Manager
Tel: 020 3469 8860
Applications from London
Mr Ewan Hughes McInnes
Research Funding Manager
Tel: 020 3469 6532
Applications from Northern England and Scotland
Ms Caroline Glover
Research Funding Manager
Tel: 0203 469 8934
Applications from all other locations
Ms Kirsty Tunna
Research Funding Manager
Tel: 0203 469 5080
More opportunities for clinical researchers
We support a broad portfolio of clinical research through grant funding, initiatives and investments in infrastructure, and we have a variety of funding schemes and other opportunities to support your research.
We are also committed to ensuring that clinical academics have the support they need to develop a career in cancer research, and we have a range of opportunities for researchers at all career levels.
Designing a clinical trial or study is a complex task, with many practical and regulatory hurdles to cross. Our Funding Managers share 13 resources to help you find advice and navigate the complexities of your study design and application.